… activation with BRAF inhibitor monotherapy. In this review, we discuss existing clinical trial
data on BRAF and MEK inhibitors together and in combinations with other therapeutic agents. …

… inhibitor (vemurafenib and dabrafenib) resistance. We also review the advantages of dual
therapy, including the addition of an MEK inhibitor (… compared to BRAF inhibitor monotherapy. …

… Another issue regarding MEK inhibition resides with the fact that positive patient response
is often short-lived. For example, despite combination therapy of BRAF and MEK inhibition’s …

… the mechanisms of resistance to combined BRAF and MEK inhibition. Because the combination
of BRAF and MEK inhibition may more effectively inhibit RAF/MEK/ERK signaling one …

… MEK inhibitor combinations have been approved for use in various cancers by the US FDA.
We review the clinical data for various BRAF plus MEK combination … combination therapy …

… and MEK inhibitors in RAS mutant tumors. The rational combination of PARP and MEK
inhibitors … in patients with RAS mutant tumors where there are few effective therapeutic options. …

… of MEK inhibitors on immune response including the potential for combination therapy of
MEK inhibitors with immunomodulatory antibodies. Combination dabrafenib/trametinib therapy …

… fewer of up to six patients experience a DLT during the first 28 days of combination therapy.
… of one such combination, trametinib (MEK inhibitor) with afuresertib (AKT inhibitor). …

… Since RAF has multiple downstream pathways, combination therapy with PI3K and MEK
inhibitors may be more effective than single-agent strategies in treating RAS-mutant melanoma. …

… that combination therapy of BRAF and MEK inhibition … But, the combination therapy also
significantly increased the incidences … , the combined BRAF and MEK inhibition will obviously be …